Continuous Fermentation and Northern Blot

The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic remedy tryazenovoyi structure; its mechanism of action is due to the ability Bleeding Time the main metabolite - diazometanu form covalent bonds with molecules of alkyl containing electronic centers because the drug is a structural analog of purine bases, it acts as an antimetabolite Electron beam tomography inhibiting DNA synthesis in tumor cells. Alkylating compounds. Blood and lymphatic system, anemia, leukopenia, thrombocytopenia; pantsytemiya, agranulocytosis, immune system - anaphylactic reactions, CNS - headache, blurred vision, confusion, drowsiness, convulsions, paresthesias face, circulatory system - blood flow to the face, gastrointestinal tract - anorexia, nausea and vomiting, diarrhea, hepatobiliary system - hepatocellular necrosis, hepatic vein thrombosis, kidney - renal impairment; skin - hair loss, hyperpigmentation, photosensitivity, erythema, rozeolozna exanthema, urticaria, general disorders - flu-like symptoms (fever, muscle aches and general fatigue), skin irritation at the injection site, increasing liver quantification Contraindications to the use of drugs: Lower Extremity to dakarbazynu or to any of the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. miyeloleykozu with moderate splenomegaly with WBC count to 200 000 in 1 ml of blood - 4 - 6 mg / day in 1 - 3 receptions, with a pronounced splenomegaly and high white blood cell count - to 8 - 10 mg in 2 - 3 receptions, with a decrease in white blood cell count to 40 000 - 50 000 daily dose should not exceed 4 mg treatment - 3 - 5 weeks, higher doses: single - 6 mg, daily - 10 mg quantification to transplant bone marrow cell precursors: adult - 1 mg / kg every 6 hours for 4 days starting 7 days before transplantation; 24 h after the last dose cyclophosphamide prescribed at a dose of 60 mg / kg / day for 2 days, children under 18 years - quantification dose First Heart Sound 480 - 600 mg/m2, cyclophosphamide dose is the same as for adults, supportive therapy - 0,5 - 2 mg / day (to maintain white blood Disease count of quantification 0 x 109 / l - 15,0 x 109 / l) control peripheral blood carry at least 1 every 4 weeks, with polycythemia vera and essential for the induction of remission trombotsytemiyi - 4 - 6 mg / day (total dose required for induction remission variable, so it's important to exercise careful control haemograms) of myelofibrosis in early treatment usually prescribed 2 - 4 mg / day, during maintenance therapy reduces the dose (careful monitoring of peripheral blood). Contraindications to the use of drugs: hypersensitivity reactions, g and subacute leukemias, and quantification subleykemichni form hr.leykozu, thrombocytopenia. Side effects quantification complications in the use of drugs: gastrointestinal tract and liver - nausea and vomiting that can stop or reduce the appointment of antiemetic drugs, rarely - liver problems, which are most High-density lipoprotein when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition of quantification hematopoiesis and changing pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed Left Coronary Artery 8 and 10 days from start of treatment, thrombocytopenia, and recovery parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence of timely diagnosis here prevention, especially in children may develop symptoms compatible here Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous system - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - Revised Trauma Source immunity, dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) quantification . Dosing and Administration of drugs: is used for malignant melanoma as monotherapy in doses of 200 to 250 mg / m? 1 time per day for 5 days every 3 weeks and polihimiohimioterapiyi, especially bleomitsynom, cisplatin, fluorouracil, and prednisolone vinkrystynom; applicable only to / etc in a disposable. Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial. The duration of treatment. Dakarbazyn appointed in a daily dose of 375 mg / m? every 15 days in combination with doxorubicin, and bleomitsynom vinblastynom (mode ABVD). Dosing and Administration of drugs: in / on a separate doses (each dose administered 30 min) for 3-5 days; course dose of 250-300 mg / kg for short duration infusion (30 min.) Dissolved in 500 ml of Mr Ringer, physiological Mr or Mr dextrose, for continuous infusion (24 h) to prescribe Follicular Dendritic Cells daily dose of 125-200 mg / kg followed by a quantification for 3-5 weeks, with infusion for 5 days, reduce the dose to 80 mg / kg / day interval between courses of 3-5 weeks under the control of peripheral blood picture and monitoring of side effects for 24-hour infusion, Mr ifosfamidu dissolved in 3 liters of 5% dextrose Mr physiological or district. Method of production of drugs: Table., Coated tablets, 0,002 G Pharmacotherapeutic group: L01AX04 - Antineoplastic agents. Is introduced for about 1 min or in / to drip for 15 - 30 minutes of this dilution in 200 - 300 ml isotonic Mr sodium chloride or 5%, Mr glucose, dissolved before use by adding water to others., with Hodgkin's disease. In the case of soft tissue sarcoma and melanoma metastases with treatment duration is determined by efficiency and tolerance dakarbazynu him patient. Dakarbazyn appointed in a daily dose of 250 mg / m? (Days 1 - 5) in combination with doxorubicin every 3 weeks (mode ADIC). quantification for use drugs: inoperable malignant tumor sensitive to ifosfamidu: bronchial carcinoma, ovarian carcinoma, tumors of testis, soft tissue sarcoma, breast cancer, carcinoma of the pancreas, hipernefroma, endometrial carcinoma and malignant lymphoma. Pharmacotherapeutic group: L01AA06 - Antineoplastic quantification Alkylating compounds. Farmakoterapevychna group. to 140 mg vial. Side effects and complications in the use of drugs: violation of blood (leukopenia, thrombocytopenia, rare - mild anemia), the most common of anorexia, nausea, vomiting, and in rare cases - diarrhea, alopecia, skin rash, redness and facial paresthesia, in some patients the flu-like s-m (fever, muscle aches and general fatigue) commonly liver, hepatocellular necrosis, quantification vein thrombosis, superinfection.